A novel topical formulation of a BRAF inhibitor significantly reduced acneiform rash associated with anti–epidermal growth factor receptor (EGFR) therapies in patients with colorectal cancer ...

Anti-EGFR therapies, such as cetuximab and panitumumab, are a cornerstone of treatment for many cancers, including colorectal cancer. However, they often cause an acneiform rash that frequently ...

One of the consequences of developing acneiform rash is treatment discontinuation or delay of EGFR-targeted therapies. In this study, Patel and her team found that treatment interruptions of anti ...

AstraZeneca, a global biopharmaceutical company is in collaboration with Revna Biosciences (www.RevnaBio.com), a precision medicine research and advanced diagnostics company to provide EGFR (Epidermal ...

Improve workflow and productivity — when patients arrive for imaging sessions without a current creatinine/eGFR workup, the StatSensor Creatinine POC testing can avoid workflow interruptions and ...

There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

The HER3-directed ADC will be tested in patients whose disease had progressed despite earlier treatment with EGFR inhibitors, including third-generation drugs like AZ's Tagrisso (osimertinib).

In acute kidney injury, certain biomarkers—such as urine albumin-to-creatinine ratio and epidermal growth factor—are linked with likelihood of eGFR nonrecovery. Serum creatinine elevations during ...

A total of 337 treatment-naïve patients with EGFR-sensitive mutation-positive locally advanced or metastatic NSCLC were enrolled and randomized 1:1 to receive either limertinib or gefitinib. The ...

During a live event, Xiuning Le, MD, PhD, discussed updated intracranial efficacy, overall survival, and safety of amivantamab plus lazertinib in patients with EGFR-mutated non–small cell lung cancer.

Join MIMS now and pay nothing for the first 30 days Join GPOnline now and pay nothing for the first 30 days ...